David Alan Campbell - Oct 28, 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Signature
/s/ James Pennington, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Oct 28, 2024
Transactions value $
-$1,338,559
Form type
4
Date filed
10/30/2024, 07:30 PM
Previous filing
Sep 27, 2024
Next filing
Nov 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Sale -$740K -13.9K -4.53% $53.22 293K Oct 28, 2024 Direct F1, F2
transaction JANX Common Stock Sale -$599K -11.1K -3.79% $53.94 282K Oct 28, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
F2 The weighted average sale price for the transaction reported was $53.2237 and the range of prices were between $52.5801 and $53.575. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $53.9412 and the range of prices were between $53.58 and $54.445. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.